Cablivi
- Prescription status not stated
- Blood, clotting and anaemia
- Active substance
- Caplacizumab
- Used in
- Blood, clotting and anaemia
- Made by
- Ablynx NV
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Cablivi is indicated for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression.
From the official label · 2026-09-30 · European Medicines Agency
How it works
From the US prescribing label for the same active substance (Cablivi). It describes the substance, not this exact product.
Caplacizumab-yhdp targets the A1-domain of vWF, and inhibits the interaction between vWF and platelets, thereby reducing both vWF-mediated platelet adhesion and platelet consumption.
The available data suggest target-bound caplacizumab-yhdp is metabolized within the liver.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-04-24
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
SpainNo exact match for this strength and form
FranceNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | Ablynx NV |
|---|---|
| Active substance | Caplacizumab |
| Used in | Blood, clotting and anaemia |
| Classification | B01A · Blood, clotting and anaemia |
| Orphan medicine | Yes — designated for a rare disease, according to the register |
| Authorised on | 2018-08-30 |
| Last updated by the regulator | 2026-05-27 |
| EMA product number | EMEA/H/C/004426 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).